Market Overview

UPDATE: BMO Capital Markets Upgrades Merck & Co. to Outperform, Reiterates $50 PT

Share:
Related MRK
Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint
Barron's Recap: Airline Stocks Ready To Soar
Exelixis-Roche's Skin Cancer Drug's FDA Review Delayed - Analyst Blog (Zacks)

In a report published Monday, BMO Capital Markets upgraded its rating on Merck & Co. (NYSE: MRK) from Market Perform to Outperform, and reiterated its $50.00 price target.

BMO Capital noted, “Merck reported impressive phase-1b data from its Anti-PD-1 cancer immunotherapy, MK-3475, which, similar to BMS'558, also appears very active in melanoma, if not more so, and is well tolerated. Moreover, impressive phase-2 data from the protease inhibitor MK-5172 support its development in an all-oral Hepatitis-C regimen based on its robust activity, once daily dosing, and lack of food effect. Following a good 3Q that showed the value of a broad portfolio coupled with strong execution, and ongoing advances in the pipeline, we believe that a rating upgrade is warranted.”

Merck & Co. closed on Friday at $44.05.

Latest Ratings for MRK

DateFirmActionFromTo
Jun 2015Piper JaffrayInitiates Coverage onNeutral
May 2015JefferiesMaintainsHold
Apr 2015Deutsche BankMaintainsHold

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Upgrades Analyst Ratings

 

Related Articles (MRK)

Around the Web, We're Loving...

Get Benzinga's Newsletters